BioPorto targets prominent new board member
Diagnostics company BioPorto proposes a prominent biotech profile and former CEO of the company Symphogen as a new member of its board of directors, to be officially elected at its general meeting in April.
BY ELIZABETH MØNSTED JOHANSEN
When the annual general meeting of the Danish diagnostics company BioPorto in held in April, the shareholders will, among other things, be asked to approve the company’s proposed board of directors. And it is set to feature a new prominent profile: Kirsten Drejer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bioporto makes management change
For abonnenter
Kirsten Drejer: “The time is right”
For abonnenter
